Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.440
+0.070 (2.95%)
At close: Nov 22, 2024, 4:00 PM
2.450
+0.010 (0.41%)
After-hours: Nov 22, 2024, 6:08 PM EST
Editas Medicine Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 9.38, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 284.43% from the current stock price of 2.44.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for EDIT stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 6 |
| Buy | 1 | 1 | 1 | 0 | 1 | 1 |
| Hold | 6 | 6 | 6 | 7 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +391.80% | Nov 5, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $8 → $5 | Hold | Maintains | $8 → $5 | +104.92% | Nov 5, 2024 |
| Stifel | Stifel | Strong Buy Maintains $17 → $11 | Strong Buy | Maintains | $17 → $11 | +350.82% | Nov 5, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $12 → $8 | Strong Buy | Maintains | $12 → $8 | +227.87% | Nov 5, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +186.89% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
35.23M
from 78.12M
Decreased by -54.91%
Revenue Next Year
14.91M
from 35.23M
Decreased by -57.67%
EPS This Year
-2.81
from -2.02
EPS Next Year
-2.42
from -2.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 76.0M | 38.9M | 89.0M | ||
| Avg | 35.2M | 14.9M | 26.2M | ||
| Low | 1.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.7% | 10.3% | 497.0% | ||
| Avg | -54.9% | -57.7% | 75.6% | ||
| Low | -97.7% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.44 | -0.42 | -1.08 | ||
| Avg | -2.81 | -2.42 | -2.34 | ||
| Low | -3.27 | -3.24 | -3.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.